ETV1 Overexpression in Prostate Cancer
Author Information
Author(s): Gasi Delila, van der Korput Hetty A., Douben Hannie C., de Klein Annelies, de Ridder Corrina M., van Weerden Wytske M., Trapman Jan
Primary Institution: Erasmus University Medical Centre, Rotterdam, The Netherlands
Hypothesis
The study investigates the genetic background of full-length ETV1 overexpression and its biological properties in prostate cancer.
Conclusion
Full-length ETV1 overexpression in clinical prostate cancer is due to genomic rearrangements involving different chromosomes.
Supporting Evidence
- ETV1 is overexpressed in a subset of clinical prostate cancers as a fusion transcript with many different partners.
- Break-apart FISH showed genomic rearrangement of the ETV1 gene in five out of six patient samples with overexpression.
- The study identified a novel, N-truncated ETV1 isoform with the same activity as full-length ETV1.
Takeaway
Some prostate cancer patients have too much of a protein called ETV1 because their genes are mixed up, which can help the cancer grow.
Methodology
The study used quantitative reverse transcriptase reaction (QPCR) and break-apart FISH to analyze ETV1 expression and genomic rearrangements in prostate cancer samples.
Limitations
The study focused on a limited number of samples and did not explore all potential genomic rearrangements.
Participant Demographics
The study involved clinical prostate cancer samples from a cohort of 66 patients.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website